Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Raccontata dabiopharmadive.commorningstar.comafr.comilsole24ore.comthenextweb.comtechfundingnews.comswissinfo.chendpoints.newsvalor.globo.combenzinga.comcityam.com